Similar articles

• Structural genomics approach to drug discovery for Mycobacterium tuberculosis.

  Ioerger TR, Sacchettini JC. Ioerger TR, et al. Curr Opin Microbiol. 2009 Jun;12(3):318-25. doi: 10.1016/j.mib.2009.04.006. Epub 2009 May 28. Curr Opin Microbiol. 2009. PMID: 19481971 Review.
• [Occurence of primary resistance in hospital patients with respiratory tuberculosis].

  Serdarević H, Bogdanović M, Travnik H, Simeonov L. Serdarević H, et al. Tuberkuloza. 1966 Jan-Jun;18(1-3):220-7. Tuberkuloza. 1966. PMID: 16296090 Bosnian. No abstract available.
• [Chemotherapy of tuberculosis with controlled viability of Mycobacteria in the sputum].

  Rudoĭ NM, Erkovskaia OIu. Rudoĭ NM, et al. Probl Tuberk. 1978 May;(5):43-7. Probl Tuberk. 1978. PMID: 97658 Russian. No abstract available.
• Natural products, small molecules, and genetics in tuberculosis drug development.

  Gutierrez-Lugo MT, Bewley CA. Gutierrez-Lugo MT, et al. J Med Chem. 2008 May 8;51(9):2606-12. doi: 10.1021/jm070719i. Epub 2008 Apr 5. J Med Chem. 2008. PMID: 18393405 Free PMC article. Review.
• [Significance of determination of drug resistance in Mycobacterium tuberculosis for successful treatment of pulmonary tuberculosis].

  Novozhilova IA. Novozhilova IA. Probl Tuberk Bolezn Legk. 2004;(4):29-31. Probl Tuberk Bolezn Legk. 2004. PMID: 15171041 Russian. No abstract available.